Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Blood and CSF Biomarkers in Amyotrophic Lateral Sclerosis: Diagnostic and Prognostic Insights from a Systematic Review and Meta-analysis

Obara, Kazuki LU orcid ; Ito, Daisuke LU ; Nilsson, Christer ; Janelidze, Shorena LU ; Santillo, Alexander LU orcid ; Katsuno, Masahisa LU and Mattsson-Carlgren, Niklas LU orcid (2026) AD/PD 2026
Abstract
Aims: Identifying reliable biomarkers is crucial for addressing diagnostic uncertainty and prognostic stratification in amyotrophic lateral sclerosis (ALS). This systematic review and meta-analysis aimed to integrate recent evidence on blood and cerebrospinal fluid (CSF) biomarkers.

Methods: We searched studies published between January 1, 2019, and March 25, 2025, investigating blood or CSF biomarkers in ALS. Eligible studies reported diagnostic accuracy, biomarker concentrations, hazard ratios (HRs) for survival, or correlations with functional rating scales or progression rate. Random-effects models pooled summary ROC curves, HRs, standardized mean differences, and correlation coefficients. Simulation analyses illustrated... (More)
Aims: Identifying reliable biomarkers is crucial for addressing diagnostic uncertainty and prognostic stratification in amyotrophic lateral sclerosis (ALS). This systematic review and meta-analysis aimed to integrate recent evidence on blood and cerebrospinal fluid (CSF) biomarkers.

Methods: We searched studies published between January 1, 2019, and March 25, 2025, investigating blood or CSF biomarkers in ALS. Eligible studies reported diagnostic accuracy, biomarker concentrations, hazard ratios (HRs) for survival, or correlations with functional rating scales or progression rate. Random-effects models pooled summary ROC curves, HRs, standardized mean differences, and correlation coefficients. Simulation analyses illustrated predictive values under varying prevalence scenarios.

Results: Forty-seven studies contributed to the diagnostic meta-analysis and 27 to the prognostic analysis, including 5,556 ALS and 3,522 controls. Neurofilament light chain (NfL) consistently showed the highest diagnostic performance. NfL yielded ≈90% pooled sensitivity and specificity against neurologically healthy controls; 81–87% against ALS mimics. Simulations highlighted prevalence-dependent predictive values: assuming 90% sensitivity and specificity, the NPV was 99% at a 5% simulated prevalence in primary care, whereas the PPV was only 32%. Even at 25–50% simulated prevalence in secondary care, PPV remained moderate. For prognosis, elevated NfL was associated with poorer survival (pooled HRs 2.7–4.3 across blood and CSF). CSF chitinases and the p-tau/t-tau ratio showed moderate diagnostic and prognostic utility, whereas most other biomarkers showed heterogeneity.

Conclusions: Among fluid biomarkers, NfL demonstrated the highest diagnostic and prognostic value, but its accuracy is limited when used alone, particularly in low-prevalence contexts. Prospective studies with external validation and harmonized methodologies are needed to establish whether additional biomarkers can complement NfL and to support biomarker-guided clinical practice and trials. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to conference
publication status
unpublished
subject
keywords
Amyotrophic Lateral Sclerosis, motor neuron disease, biomarker, systematic review, meta-analysis
conference name
AD/PD 2026
conference location
Copenhagen, Denmark
conference dates
2026-03-17 - 2026-03-21
project
Fluid biomarkers for Diagnosis, Prognosis and Monitoring of Amyotrophic Lateral Sclerosis
language
English
LU publication?
yes
id
7d126d3b-25c2-4396-9426-f1a8aa7e364d
date added to LUP
2026-04-18 16:08:30
date last changed
2026-04-20 08:03:06
@misc{7d126d3b-25c2-4396-9426-f1a8aa7e364d,
  abstract     = {{Aims: Identifying reliable biomarkers is crucial for addressing diagnostic uncertainty and prognostic stratification in amyotrophic lateral sclerosis (ALS). This systematic review and meta-analysis aimed to integrate recent evidence on blood and cerebrospinal fluid (CSF) biomarkers.<br/><br/>Methods: We searched studies published between January 1, 2019, and March 25, 2025, investigating blood or CSF biomarkers in ALS. Eligible studies reported diagnostic accuracy, biomarker concentrations, hazard ratios (HRs) for survival, or correlations with functional rating scales or progression rate. Random-effects models pooled summary ROC curves, HRs, standardized mean differences, and correlation coefficients. Simulation analyses illustrated predictive values under varying prevalence scenarios.<br/><br/>Results: Forty-seven studies contributed to the diagnostic meta-analysis and 27 to the prognostic analysis, including 5,556 ALS and 3,522 controls. Neurofilament light chain (NfL) consistently showed the highest diagnostic performance. NfL yielded ≈90% pooled sensitivity and specificity against neurologically healthy controls; 81–87% against ALS mimics. Simulations highlighted prevalence-dependent predictive values: assuming 90% sensitivity and specificity, the NPV was 99% at a 5% simulated prevalence in primary care, whereas the PPV was only 32%. Even at 25–50% simulated prevalence in secondary care, PPV remained moderate. For prognosis, elevated NfL was associated with poorer survival (pooled HRs 2.7–4.3 across blood and CSF). CSF chitinases and the p-tau/t-tau ratio showed moderate diagnostic and prognostic utility, whereas most other biomarkers showed heterogeneity.<br/><br/>Conclusions: Among fluid biomarkers, NfL demonstrated the highest diagnostic and prognostic value, but its accuracy is limited when used alone, particularly in low-prevalence contexts. Prospective studies with external validation and harmonized methodologies are needed to establish whether additional biomarkers can complement NfL and to support biomarker-guided clinical practice and trials.}},
  author       = {{Obara, Kazuki and Ito, Daisuke and Nilsson, Christer and Janelidze, Shorena and Santillo, Alexander and Katsuno, Masahisa and Mattsson-Carlgren, Niklas}},
  keywords     = {{Amyotrophic Lateral Sclerosis; motor neuron disease; biomarker; systematic review; meta-analysis}},
  language     = {{eng}},
  month        = {{03}},
  title        = {{Blood and CSF Biomarkers in Amyotrophic Lateral Sclerosis: Diagnostic and Prognostic Insights from a Systematic Review and Meta-analysis}},
  url          = {{https://lup.lub.lu.se/search/files/247842003/ObaraK_etal_ADPD2026_ePoster.pdf}},
  year         = {{2026}},
}